IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

IQVIA Holdings Inc.

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on IQVIA Holdings yesterday and set a price target of $250.00. The company’s sh...

Evercore ISI Sticks to Its Buy Rating for IQVIA Holdings (IQV)

IQVIA Holdings (($IQV)) announced an update on their ongoing clinical study. Study Overview: The study titled Observational Cohort Study on Adult P...

Cenobamate’s Real-World Impact: A New Hope for Focal Epilepsy?

IQVIA Holdings (($IQV)) announced an update on their ongoing clinical study. Study Overview: The QUVIVIQ® Pregnancy Registry, officially titled ‘Re...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IQV	$224.90	+3.59%	1.45M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IQV	$224.90	+3.6%	1.45M
3
4
5
6

IQV

IQV

Latest News for IQV

Get IQVIA Holdings Inc. Data in Excel

Get IQVIA Holdings Inc. Data in Excel